Toxicological Research

Korean Society of Toxicology & Korea Environmental Mutagen Society (한국독성학회)
권호 표지

Cancer Gene Therapy. History and Major Developments

암 유전자 치료제의 개발 현황

  • Published : 2003.09.01
Download PDF
⟨ Previous Next ⟩

Abstract

Medicine is undergoing a revolution in the understanding of the mechanisms through which disease processes develop. The advent of genetics and molecular biology to oncology not only is providing surrogate predictors of therapy response and survival which are forming the basis for selection among established treatment options, but is providing targets for new directions in therapy as well. Molecular modification of somatic cells for the purposes of protecting the normal cells from the toxicity of cancer chemotherapy, for the sensitization of the tumor cells to therapy and use of conditionally replicating viral vector have been new directions of cancer treatment which have reached the clinical arena. Advances in molecular pharmacology and vector design summarized in this paper may provide solutions to some of the existing problems in the technology of gene transfer therapy. Continued basic research into the biological basis of human disease, systemic studies of the application of these discoveries to therapy and the improvement of vector for gene delivery all combined may result in advances in this important field of therapy over the next few years.

Keywords

References

  1. Cancer Gene Ther. v.10 The cytotoxic effect of replication competent adenoviral vectors carrying L-plastin promoter regulated E1A and cytosine deaminase genes in cancers of the Breast, ovary and colon Akbulut,H.;Zhang,L.;Tang,Y.;Deisseroth,A. https://doi.org/10.1038/sj.cgt.7700579
  2. Science v.274 An adenovirus mutant that replicates selectively in p53-deficient human tumor cells Bischoff,J.R.;Kim,D.H.;Williams,A.;Heise,C.;Horn,S.;Muna,M.;Ng,L.;Nye,J.A.;Sampson-Johannes,A.;Fattaey,A.;McCormick,F. https://doi.org/10.1126/science.274.5286.373
  3. J. Virol. v.73 p53-Independent and -dependent requirements for E1B-55K in adenovirus type 5 replication Harada,J.N.;Berk,A.J.
  4. Science v.288 Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease Cavazzana-Calvo,M.;Hacein-Beym,S.;de Saint Basile,G.;Gross,F.;Yvon,E.;Nusbaum,P.;Selz,F.;Hue,C.;Certain,S.;Casanova,J.L.;Bousso,P.;Deistm,F.L.;Fischer,A. https://doi.org/10.1126/science.288.5466.669
  5. Cancer Gene Ther. v.6 Use of L-plastin promoter to develop an adenoviral system that confers transgene expression in ovarian cancer cells but not in normal mesothelial cells Chung,I.;Schwartz,P.E.;Crystal,R.G.;Pizzorno,G.;Leavitt,J.;Deisseroth,A.B. https://doi.org/10.1038/sj.cgt.7700017
  6. Gene Ther. v.8 In vivo gene therapy for colon cancer using adenovirus-mediated, transfer of the fusion gene cytosine deaminase and uracil phosphoribosyltransferase Chung-Faye,G.A.;Chen,M.J.;Green,N.K.;Burton,A.;Anderson,D.;Mautner,V.;Searle,P.F.;Kerr,D.J. https://doi.org/10.1038/sj.gt.3301557
  7. J. Clin. Onc. v.16 Adenovirus-mediated p53 gene transfer in patients with advanced recurrent head and neck squamous cell carcinoma Clayman,G.L.;el-Naggar,A.K.;Lippman,S.M.;Henderson,Y.C.;Frederick,M.;Merritt,J.A.;Zumstein,L.A.;Timmons,T.M.;Liu,T.J.;Ginsberg,L.;Roth,J.A.;Hong,W.K.;Bruso,P.;Goepfert,H. https://doi.org/10.1200/JCO.1998.16.6.2221
  8. Human Gene Ther. v.8 Phase I study of direct administration of a replication deficient adenovirus vector containing the E. coli cytosine deaminase gene to metastatic colon carcinoma of the liver in association with the oral administration of the pro-drug 5-fluorocytosine Crystal,R.G.;Hirschowitz,E.;Lieberman,M.;Daly,J.;Kazam,E.;Henschke,C.;Yankelevitz,D.;Kemeny,N.;Silverstein,R.;Ohwada,A.;Russi,T.;Mastrangeli,A.;Sanders,A.;Cooke,J.;Harvey,B.G. https://doi.org/10.1089/hum.1997.8.8-985
  9. Human Gene Ther. v.7 Use of safety-modified retroviruses to introduce chemotherapy resistance sequences into normal hematopoietic cells for chemoprotection during the therapy of breast cancer. a pilot trial Deisseroth,A.B.;Holmes,F.;Hortobagyi,G.;Champlin,R. https://doi.org/10.1089/hum.1996.7.3-401
  10. SUMMARY MINUTES Meeting #33 Center for Biologics Evaluation and Research, Biological Response Modifiers Advisory Committee FDA (Food and Drug Administration)
  11. SUMMARY MINUTES Meeting #34 Center for Biologics Evaluation and Research, Biological Response Modifiers Advisory Committee FDA (Food and Drug Administration)
  12. Cancer Res. v.53 The "bystander effect": tumor regression when a fraction of the tumor mass is genetically modified Freeman,S.M.;Abboud,C.N.;Whartenby,K.A.;Packman,C.H.;Koeplin,D.S.;Moolten,F.L.;Abraham,G.N
  13. Human Gene Ther. v.9 A novel three-pronged approach to kill cancer cells selectively: concomitant viral, double suicide gene, and radiotherapy Freytag,S.O.;Rogulski,K.R.;Paielli,D.L.;Gilbert,J.D.;Kim,J.H. https://doi.org/10.1089/hum.1998.9.9-1323
  14. Cancer Res. v.62 Phase I study of replication-competent adenovirus-mediated double suicide gene therapy for the treatment of locally recurrent prostate cancer Freytag,S.O.;Khil,M.;Stricker,H.;Peabody,J.;Menon,M.;DePeralta-Venturina,M.;Nafziger,D.;Pegg,J.;Paielli,D.;Brown,S.;Barton,K.;Lu,M.;Aguilar-Cordova,E.;Kim,J.H.
  15. Int. J. Rad. Onc. Bio. Phys. v.54 Efficacy and toxicity of replication-competent adenovirus-mediated double suicide gene therapy in combination with radiation therapy in an orthotopic mouse prostate cancer model Freytag,S.O.;Paielli,D.;Wing,M.;Rogulski,K.;Brown,S.;Kolozsvary,A.;Seely,J.;Barton,K.;Dragovic,A.;Kim,J.H. https://doi.org/10.1016/S0360-3016(02)03005-5
  16. Blood v.92 Cytosine deaminase adenoviral vector and 5-fluorocytosine selectively reduce breast cancer cells 1 millon-fold when they contaminate hematopoietic cells: a potential purging method for autologous transplantation Garcia-Sanchez,F.;Pizzomo,G.;Fu,S.Q.;Nanakorn,T.;Krause,D.S.;Liang,J.;Adams,E.;Leffert,J.J.;Yin,L.H.;Cooperberg,M.R.;Hanania,E.;Wang,W.L.;Won,J.H.;Peng,X.Y.;Cote,R.;Brown,R.;Burtness,B.;Giles,R.;Crystal,R.;Deisseroth,A.B.
  17. Proc. Natl. Acad. Sci. USA v.93 Results of MDR-1 vector modification trial indicate that granulocyte/macrophage colonyforming unit cells do not contribute to posttransplant hematopoietic recovery following intensive systemic therapy Hanania,E.G.Giles,R.E.;Kavanagh,J.;Fu,S.Q.;Ellerson,D.;Zu,Z.;Wang,T.;Su,Y.;Kudelka,A.;Rahman,Z.;Holmes,F.;Hortobagyi,G.;Claxton,D.;Bachier,C.;Thall,P.;Cheng,S.;Hester,J.;Ostrove,J.M.;Bird,R.E.;Chang,A.;Korbling,M.;Seong,D.;Cote,R.;Holzmayer,T.;Deisseroth,A.B. https://doi.org/10.1073/pnas.93.26.15346
  18. World J. Urol. v.18 Prospects for herpes-simplex-virus thymidine-kinase and cytokine gene transduction as immunomodulatory gene therapy for prostate cancer Hassan,W.;Sanford,M.A.;Woo,S.L.;Chen,S.H.;Hall,S.J. https://doi.org/10.1007/s003450050185
  19. Cancer Gene Ther. v.7 Synergistic effects of adenovirus expressing wild-type p53 on chemosensitivity of nonsmall cell lung cancer cells Horio,Y.;Hasegawa,Y.;Sekido,Y.;Takahashi,M.;Roth,J.A.;Shimokata,K. https://doi.org/10.1038/sj.cgt.7700148
  20. Cancer Res. v.53 In vivo antitumor activity of 5-fluorocytosine on human colorectal carcinoma cells genetically modified to express cytosine deaminase Huber,B.E.;Austin,E.A.;Good,S.S.;Knick,V.C.;Tibbels,S.;Richards,C.A.
  21. Proc. Natl. Acad. Sci. USA v.91 Metabolism of 5-fluorocytosine to 5-fluorouracil in human colorectal tumor cells transduced with the cytosine deaminase gene: significant antitumor effects when only a small percentage of tumor cells express cytosine deaminase Huber,B.E.;Austin,E.A.;Richards,C.A.;Davis,S.T.;Good,S.S. https://doi.org/10.1073/pnas.91.17.8302
  22. Nature Gen. v.17 Sustained expression of genes delivered directly into liver and muscle by lentiviral vectors Kafri,T.;Blomer,U.;Peterson,D.A.;Gage,F.H.;Verma,I.M. https://doi.org/10.1038/ng1197-314
  23. Cancer Res. v.62 Efficient and nontoxic adenoviral purging method for autologous transplantation in breast cancer patients Lillo,R.;Ramirez,M.;Alvarez,A.;Santos,S.;Garcia-Castro,J.;Fernandez de Velasco,J.;Aviles,M.J.;Gomez-Pineda,A.;Diez,J.L.;Balas,A.;Vicario,J.L.;Bueren,J.A.;Garcia-Sanchez,F.
  24. Human Gene Ther. v.12 Clinical protocol. A Phase 1 open-label clinical trial of the safety and tolerability of single escalating doses of autologous CD4 T cells transduced with VRX496 in HIV-positive subjects MacGregor,R.R.
  25. J. Exp. Clin. Cancer Res. v.19 Progress towards gene therapy for cancer Marchisone,C.;Pfeffer,U.;Del Grosso,F.;Noonan,D.M.;Santi,L.;Albin,I.A.
  26. Science v.286 Gene therapy death prompts review of adenovirus vector Marshall,E. https://doi.org/10.1126/science.286.5448.2244
  27. Nat. Rev. Cancer v.1 Cancer gene therapy: fringe or cutting edge? McCormick,F. https://doi.org/10.1038/35101008
  28. Nature Med. v.1 Attenuated multi-mutated herpes simplex virus-1 for the treatment of malignant gliomas Mineta,T.;Rabkin,S.D.;Yazaki,T.;Hunter,W.D.;Martuza,R.L. https://doi.org/10.1038/nm0995-938
  29. Gene Ther. v.9 Double suicide gene therapy using a replication defective herpes simplex virus vector reveals reciprocal inteference in a malignant gloma model Moriuchi,S.;Wolfe,D.;Tamura,M.;Yoshimine,T.;Miura,F.;Cohen,J.B.;Glorioso,J.C. https://doi.org/10.1038/sj.gt.3301693
  30. Cancer Res. v.46 Tumor chemosensitivity conferred by inserted herpes thymidine kinase genes: [aradigm for a prospective cancer control strategy Moolten,F.L.
  31. J. Clin. Onc. v.18 Adenovirus-mediated p53 gene transfer in sequence with cisplatin to tumors of patients with non-small-cell lung cancer Nemunaitis,J.;Swisher,S.G.;Timmons,T.;Connors,D.;Mack,M.;Doerksen,L.;Weill,D.;Wait,J.;Lawrence,D.D.;Kemp,B.L.;Fossella,F.;Glisson,B.S.;Hong,W.K.;Khuri,F.R.;Kurie,J.M.;Lee,J.J.;Lee,J.S.;Nguyen,D.M.;Nesbitt,J.C.;Perez-Soler,R.;Pisters,K.M.;Putnam,J.B.;Richli,W.R.;Shin,D.M.;Walsh,G.L. https://doi.org/10.1200/JCO.2000.18.3.609
  32. J. Clin. Onc. v.19 Phase II trial of intratumoral administration of ONYX-015, a replication-selective adenovirus, in patients with refractory head and neck cancer Nemunaitism,J.;Khuri,F.;Ganly,I.;Arseneau,J.;Posner,M.;Vokes,E.;Kuhn,J.;McCarty,T.;Landers,S.;Blackburn,A.;Romel,L.;Randlev,B.;Kaye,S.;Kim,D. https://doi.org/10.1200/JCO.2001.19.2.289
  33. Expert Opinion on Biological Therapy v.2 Head and neck cancer: gene therapy approaches. Part II: genes delivered Nemunaitis,J.;O'Brien,J. https://doi.org/10.1517/14712598.2.3.311
  34. Clin. Cancer Res. v.7 Synergistic inhibition of human lung cancer cell growth by adenovirus-mediated wild-type p53 gene transfer in combination with docetaxel and radiation therapeutics in vitro and in vivo Nishizaki,M.;Meyn,R.E.;Levy,L.B.;Atkinson,E.N.;White,R.A.;Roth,J.A.;Ji,L.
  35. J. Clin. Onc. v.17 Genetic prodrug activation therapy for breast cancer: A phase I clinical trial of erbB-2-directed suicide gene expression Pandha,H.S.;Martin,L.A.;Rigg,A.;Hurst,H.C.;Stamp,G.W.;Sikora,K.;Lemoine,N.R. https://doi.org/10.1200/JCO.1999.17.7.2180
  36. Anti-cancer Drugs v.13 Efficient induction of apoptosis by ONYX-015 adenovirus in human colon cancer cell lines regardless of p53 status Petit,T.;Davidson,K.K.;Cerna,C.;Lawrence,R.A.;Von Hoff,D.D.;Heise,C.;Kirn,D.;Izbicka,E. https://doi.org/10.1097/00001813-200201000-00005
  37. Clinical Cancer Res. v.4 Chemotherapy immediately following autologous stem-cell transplantation in patients with advanced breast cancer Rahman,Z.;Kavanagh,J.;Champlin,R.;Giles,R.;Hanania,E.;Fu,S.;Zu,Z.;Mehra,R.;Holmes,F.;Kudelka,A.;Claxton,D.;Verschraegen,C.;Gajewski,J.;Andreeff,M.;Heimfeld,S.;Berenson,R.;Ellerson,D.;Calvert,L.;Mechetner,E.;Holzmayer,T.;Dayne,A.;Hamer,J.;Bachier,C.;Ostrove,J.;Deisseroth,A.
  38. Cancer Gene Ther. v.8 Temozolomide enhances herpes simplex virus thymidine kinase/ganciclovir therapy of malignant glioma Rainov,N.G.;Fels,C.;Droege,J.W.;Schafer,C.;Kramm,C.M.;Chou,T.C. https://doi.org/10.1038/sj.cgt.7700355
  39. Cancer Res. v.57 Prostate attenuated replication competent adenovirus (ARCA) CN706: a selective cytotoxic for prostate-specific antigen-positive prostate cancer cells Rodriguez,R.;Schuur,E.R.;Lim,H.Y.;Henderson,G.A.;Simons,J.W.;Henderson,D.R.
  40. J. Clin. Onc. v.19 Adenovirus-mediated wild-type p53 gene transfer in patients receiving chemotherapy for advanced non-small-cell lung cancer results of a multicenter phase II study. Schuler,M.;Herrmann,R.;De Greve,J.L.;Stewart,A.K.;Gatzemeier,U.;Stewart,D.J.;Laufman,L.;Gralla,R.;Kuball,J.;Buhl,R.;Heussel,C.P.;Kommoss,F.;Perruchoud,A.P.;Shepherd,F.A.;Fritz,M.A.;Horowitz,J.A.;Huber,C.;Rochlitz,C. https://doi.org/10.1200/JCO.2001.19.6.1750
  41. Cancer Res. v.56 Adenovirus-mediated gene transfer to human breast tumor cells: an approach for cancer gene therapy and bone marrow purging Seth,P.;Brinkmann,U.;Schwartz,G.N.;Katayose,D.;Gress,R.;Pastan,I.;Cowan,K.
  42. Human Gene Ther. v.10 A phase 1-2 clinical trial of gene therapy for recurrent glioblastoma multiforme by tumor transduction with the herpes simplex thymidine kinase gene followed by ganciclovir. GLI328 European-Canadian Study Group Shand,N.;Weber,F.;Mariani,L.;Bernstein,M.;Gianella-Borradori,A.;Long,Z.;Sorensen,A.G.;Barbier,N. https://doi.org/10.1089/10430349950016979
  43. J. National Cancer Institute v.91 Adenovirus-mediated p53 gene transfer in advanced non-small-cell lung cancer Swisher,S.G.;Roth,J.A.;Nemunaitis,J.;Lawrence,D.D.;Kemp,B.L.;Carrasco,C.H.;Connors,D.G.;El-Naggar,A.K.;Fossella,F.;Glisson,B.S.;Hong,W.K.;Khuri,F.R.;Kurie,J.M.;Lee,J.J.;Lee,J.S.;Mack,M.;Merritt,J.A.;Nguyen,D.M.;Nesbitt,J.C.;Perez-Soler,R.;Pisters,K.M.;Putnam,B.Jr.;Richli,W.R.;Savin,M.;Waugh,M.K. https://doi.org/10.1093/jnci/91.9.763
  44. Human Gene Ther. v.9 Enhancement of the herpes simplex virus thymidine kinase/ganciclovir bystander effect and its antitumor efficacy in vivo by pharmacologic manipulation of gap junctions Touraine,R.L.;Vahanian,N.;Ramsey,W.J.;Blaese,R.M. https://doi.org/10.1089/hum.1998.9.16-2385